Clinical oncology (Royal College of Radiologists (Great Britain)) · 2025
Pioneering Change in Radiotherapy With Biological Adaptive Radiotherapy for Lung Volumetric Modulated Radiotherapy (VMAT) Patients.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kawahara D, Koganezawa A S, Yamaguchi H, Wada T, Murakami Y
Аннотация
AIMS: To introduce a Biological Adaptive Radiotherapy (BART) framework that incorporates biological effects into adaptive planning, quantify the impact of a short intrafraction interruption on biologically effective dose (BED) in stage III non-small cell lung cancer treated with volumetric modulated arc therapy (VMAT), and evaluate a compensation strategy designed to restore target BED while respecting organs-at-risk (OAR) constraints.
METHODS: We analysed lung non-small cell cancer patients with stage III treated using VMAT with two full arcs. A microdosimetric kinetic model (MKM) was used to calculate BED reductions caused by a 120-minute interruption after the first arc. Compensation plans were generated by converting deviations in biological dose into physical dose adjustments, which were optimised using a treatment planning system (TPS). Dose-volume histograms (DVHs) and other metrics were compared for plans with and without interruptions and after BART compensation.
RESULTS: Interruption An interruption caused BED reductions in planning target volume, with the dose difference of the D98% and D2% differences of 15.7%-16.5% and 5.2%-14.5%, respectively. For a normal lung, volume differences at 5 Gy (V5Gy) and 20 Gy (V20Gy) ranged from 0.7% to 2.2% and 0.3% to 4.7%, respectively. With dose compensation, the dose differences reduced to 0.8%-1.4% for the D98% and 1.4%-8.3% for the D2%. The difference of the V5Gy and V20Gy also decreased to 1.0%-4.1% and 0.4%-2.6%, respectively. Spinal cord dose constraints were met across all plans.
CONCLUSION: The BART framework effectively compensates for BED reductions due to short-term treatment interruptions, preserving therapeutic efficacy and adhering to organ at risk (OAR) constraints. This innovative approach represents a transformative advancement in adaptive radiation therapy by integrating biological considerations, enhancing treatment precision and personalisation.
METHODS: We analysed lung non-small cell cancer patients with stage III treated using VMAT with two full arcs. A microdosimetric kinetic model (MKM) was used to calculate BED reductions caused by a 120-minute interruption after the first arc. Compensation plans were generated by converting deviations in biological dose into physical dose adjustments, which were optimised using a treatment planning system (TPS). Dose-volume histograms (DVHs) and other metrics were compared for plans with and without interruptions and after BART compensation.
RESULTS: Interruption An interruption caused BED reductions in planning target volume, with the dose difference of the D98% and D2% differences of 15.7%-16.5% and 5.2%-14.5%, respectively. For a normal lung, volume differences at 5 Gy (V5Gy) and 20 Gy (V20Gy) ranged from 0.7% to 2.2% and 0.3% to 4.7%, respectively. With dose compensation, the dose differences reduced to 0.8%-1.4% for the D98% and 1.4%-8.3% for the D2%. The difference of the V5Gy and V20Gy also decreased to 1.0%-4.1% and 0.4%-2.6%, respectively. Spinal cord dose constraints were met across all plans.
CONCLUSION: The BART framework effectively compensates for BED reductions due to short-term treatment interruptions, preserving therapeutic efficacy and adhering to organ at risk (OAR) constraints. This innovative approach represents a transformative advancement in adaptive radiation therapy by integrating biological considerations, enhancing treatment precision and personalisation.